LATEST FROM IPOX^®

News

News and updates from IPOX^®, including media mentions, interviews, research and press releases.

Media mentions · Reuters

Reuters: IPOX^® VP Kat Liu Comments on Iambic Therapeutics’ AI Drug Discovery Platform and IPO Valuation

Nvidia-backed Iambic Therapeutics is seeking to raise up to $159.4 million in its U.S. IPO, targeting a valuation of up to $805.8 million. IPOX^® Vice President Kat Liu told Reuters that Iambic’s value depends primarily on its drug pipeline and prospects for approval and commercialization. The company uses AI to develop cancer treatments and plans to list on Nasdaq as “IAM,” as biotech attracts investor interest despite rising Treasury yields, market volatility, and geopolitical tensions affecting the broader IPO market.

October 9, 2026Kat Liu

Media mentions · Fortune

Fortune: IPOX^® VP Kat Liu Comments on Oura’s Postponed IPO and Valuation Questions

IPOX^® VP Kat Liu was interviewed for Fortune on Oura’s decision to postpone its IPO, offering perspective on valuation concerns, deal structure, and investor expectations. Liu discussed how Oura’s positioning as either a digital-health platform or consumer hardware company could shape valuation views, while also noting the market signal created by a high proportion of secondary shares.

October 6, 2026Kat Liu

Media mentions · Reuters

Reuters: IPOX^® Associate Lukas Muehlbauer Comments on Airtel Money’s London IPO

Reuters reports that Airtel Money is targeting a valuation of approximately $7 billion in its London IPO, which could become the city’s largest offering since September 2025. IPOX^® Associate Lukas Muehlbauer said the deal demonstrates London’s ability to attract sizable international listings while also reflecting a buyer’s market. He noted that companies must remain realistic about valuation as Airtel Money prepares to raise about $703 million through the sale of 270 million shares ahead of its October debut.

October 1, 2026Lukas Muehlbauer

Media mentions · Reuters

Reuters: IPOX^® Associate Lukas Muehlbauer Comments on Oura IPO Delay and Market Conditions

Reuters reports that Oura postponed its planned U.S. IPO as market volatility and higher interest rates increased investor caution toward new listings. IPOX^® Associate Lukas Muehlbauer commented that higher rates are making investors more selective, particularly on growth valuations, while noting that the IPO window remains open. He also highlighted reported demand for Oura’s offering, which was said to be around four times oversubscribed, and pointed to Anthropic’s planned IPO as an important upcoming market test.

October 1, 2026Lukas Muehlbauer

Media mentions · Reuters

Reuters: IPOX^® VP Kat Liu Discusses Investor Selectivity in Accelevation’s AI Infrastructure IPO

Reuters reports that Accelevation is targeting a valuation of up to $5.37 billion in its U.S. IPO, seeking to raise up to $720 million. IPOX^® Vice President Kat Liu said investors are becoming more selective as AI infrastructure offerings expand, focusing on companies’ value-chain positioning, backlog quality, and ability to convert demand into revenue, margins, and cash flow. Accelevation provides power distribution, cooling, and modular infrastructure for data centers supporting growing AI computing demand.

September 25, 2026Kat Liu

Media mentions · Barron's

Barron's: IPOX^® Founder Josef Schuster Comments on Retail Access to IPO Allocations

IPOX^® CEO Josef Schuster commented in Barron's on how growing retail access to IPO allocations through platforms such as Robinhood, SoFi and Coinbase could influence short-term trading in newly listed companies. Discussing Oura’s upcoming IPO, Schuster noted that restrictions on future IPO access may discourage investors from quickly selling allocated shares, potentially affecting early trading dynamics. The article also highlighted IPOX^®’s broader role in IPO market research and its index tracked by the First Trust US Equity Opportunities ETF.

September 25, 2026Josef Schuster

Media mentions · Kauppalehti

Kauppalehti: IPOX^® Associate Lukas Muehlbauer Discusses Oura’s IPO and Growth Outlook

IPOX^® Associate Lukas Muehlbauer was interviewed by Kauppalehti, Finland’s leading business and financial newspaper, about Oura’s planned U.S. IPO and growth outlook. The article examines Oura’s strong revenue momentum, targeted $12.8–14.1 billion valuation and offering structure. Muehlbauer discussed how the valuation reflects significant future growth expectations and noted that much of the stock being offered comes from existing shareholders, meaning Oura itself is expected to receive only a portion of the proceeds raised through the transaction as part of the IPO.

September 25, 2026Lukas Muehlbauer

Media mentions · Reuters

Reuters: IPOX^® Research Associate Lukas Muehlbauer Comments on ADARx IPO Debut and Biotech Market Momentum (Updated)

Reuters reports that ADARx Pharmaceuticals raised $446.3 million in an upsized U.S. IPO, with shares opening 30% above the $17 offer price. IPOX^® Associate Lukas Muehlbauer, who commented ahead of the offering on AbbVie’s backing and biotech investor selectivity, spoke with Reuters again after the company began trading. He highlighted AbbVie’s validation, ADARx’s Phase 3 lead drug and broader development platform, while noting that investors remain focused on mature clinical assets and key catalyst milestones across the biotech IPO market.

September 22, 2026Lukas Muehlbauer

Media mentions · Reuters

Reuters: IPOX^® VP Kat Liu Comments on Oura’s $15.6 Billion IPO Valuation

IPOX^® VP Kat Liu comments on Oura’s planned U.S. IPO, which targets a fully diluted valuation of about $15.6 billion and could raise up to $2.2 billion. Liu highlighted Oura’s beginner-friendly, fashionable positioning in wearables, while noting that the valuation reflects expectations for continued strong growth and a greater shift toward higher-margin recurring revenue. Oura is expected to price next week and trade on Nasdaq under the ticker OURA, following its fall roadshow launch.

September 21, 2026Kat Liu

News

Stay ahead of the next listing.